The AcroImmune Innovative Large Molecule Drug R&D Center has cumulatively invested approximately RMB 280 million, with a team of 70 researchers. Multiple products are currently under development, focusing on creating innovative immunotherapy drugs and striving to bring more best-in-class products to clinical patients. Antibody-drug conjugates (ADCs) are a novel type of cancer treatment that combines chemotherapy and immunotherapy, becoming a popular focus for global pharmaceutical companies. "Choosing Nanjing Jiangning is due to its favorable investment and talent environment," said Liu Yang, founder and chairman of the company. The Nanjing R&D center already has three projects entering clinical stages, with technology transfer and service revenues exceeding USD 14 million. It is expected that within five years of product launch, cumulative output value will not be less than RMB 5 billion, with cumulative tax contributions not less than RMB 450 million.
